

Table S5. Overall survival at 3 years and 5 years in META-Analysis

	First Author	Year	Guidance-Modality	Procedure	HR (95% CI)
Overall survival at 3 years	Wu, J	2015	CT vs. US	RFA	1.33 (0.36-4.84)*
	Lee, L	2017	CT vs. US	RFA	1.25 (0.38-4.21)
	Hermida, M.	2018	CT vs. US	RFA/MWA	1.44 (0.21-10.03)*
	Huo, J	2019	CT vs. US	RFA	0.98 (0.74-1.30)*
	Liu, Z	2019	CT vs. US	RFA	2.58 (0.69-9.56)*
	Yuan, C	2019	CT vs. US	RFA	0.42 (0.04-4.96)*
			CT vs. MR		0.31 (0.07-1.40)*
			MR vs. US		0.76 (0.10-5.74)*
	Li, Z	2021	CT vs. MR	MWA	2.42 (0.24-24.76)*
	Wu, C	2021	CT vs. US	RFA	1.19 (0.30-4.73)*
Overall survival at 5 years	Yu, Z	2021	CT vs. US	RFA	0.63 (0.22-1.74)*
	Wu, J	2015	CT vs. US	RFA	1.26 (0.46-3.43)*
	Huo, J	2019	CT vs. US	RFA	1.22 (0.96-1.56)
	Li, Z	2021	CT vs. MR	MWA	0.81 (0.34-1.94)
	Wu, C	2021	CT vs. US	RFA	1.88 (0.63-5.60)

CT, Computed Tomography; MR, Magnetic Resonance; US, Ultrasound; RFA, Radiofrequency Ablation; MWA, Microwave Ablation; HR, Hazard Ratio; CI, Confidence Interval.

* Data extracted from the survival curve